Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-week, Multicenter, Randomized, Open-Label, Parallel-group Study Comparing the Efficacy and Safety of Toujeo and Tresiba in Insulin-NaivePatients With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Trial Profile

A 24-week, Multicenter, Randomized, Open-Label, Parallel-group Study Comparing the Efficacy and Safety of Toujeo and Tresiba in Insulin-NaivePatients With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin degludec
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms BRIGHT
  • Sponsors Sanofi
  • Most Recent Events

    • 01 Jul 2021 Results of subanalysis assessing efficacy and safety of Gla-300 versus IDeg-100 in predefined (less than or greater than equal to 65 years) and post hoc (less than or greater than equal to 70 years) age group with type 2 diabetes, published in the Diabetes, Obesity and Metabolism.
    • 25 Sep 2020 Results from real-world studies ACHIEVE, REACH, REGAIN, and RCTs EDITION 1-3 and BRIGHT assessing Treatment satisfaction in people with type 2 diabetes receiving basal insulin, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
    • 06 Dec 2019 Results of post-hoc analysis assessing HbA1c change and incidence and rates of hypoglycaemia presented at the 2019 Congress of the International Diabetes Federation.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top